August 26, 2010
Dear Colleagues,
The Alzheimer’s Association is soliciting comments and recommendations regarding proposed changes to the diagnoses of Alzheimer’s disease, Mild Cognitive Impairment, and a new designation of “Pre-clinical Alzheimer’s Disease.” The recommendations of three work groups, convened by the National Institute on Aging and the Alzheimer’s Association designated for compiling these proposed changes, can be viewed at http://www.alz.org/research/diagnostic_criteria/
The Association wishes to obtain comments as soon as possible, and these can be submitted to Maria C Carrillo, Ph.D., at (maria.carrillo@alz.org).
Members are encouraged to view these recommendations and submit their opinions. Changes in the diagnostic criteria of Alzheimer’s disease, mild cognitive impairment, and the inclusion of a new diagnostic category are important issues. They will affect all of us, directly or indirectly.
When examining the criteria, please consider the effects of implementation of these criteria, and how implementation would affect you, your relatives, and your clients. Issues you may wish to consider include the emphasis on the use of biomarkers as part of the diagnostic process, the role of neuropsychological assessment in the diagnostic process, effects of receiving diagnoses in the absence of a current means of preventing or stopping the progress of Alzheimer’s disease, and treatment recommendations for persons who receive any of these diagnoses.
Now is the time to be engaged in this process, and to let the voices of psychologists who specialize in adult development and aging be heard.
Sincerely,
Cameron J. Camp, Ph.D.
President – Div. 20
Dear Colleagues,
The Alzheimer’s Association is soliciting comments and recommendations regarding proposed changes to the diagnoses of Alzheimer’s disease, Mild Cognitive Impairment, and a new designation of “Pre-clinical Alzheimer’s Disease.” The recommendations of three work groups, convened by the National Institute on Aging and the Alzheimer’s Association designated for compiling these proposed changes, can be viewed at http://www.alz.org/research/diagnostic_criteria/
The Association wishes to obtain comments as soon as possible, and these can be submitted to Maria C Carrillo, Ph.D., at (maria.carrillo@alz.org).
Members are encouraged to view these recommendations and submit their opinions. Changes in the diagnostic criteria of Alzheimer’s disease, mild cognitive impairment, and the inclusion of a new diagnostic category are important issues. They will affect all of us, directly or indirectly.
When examining the criteria, please consider the effects of implementation of these criteria, and how implementation would affect you, your relatives, and your clients. Issues you may wish to consider include the emphasis on the use of biomarkers as part of the diagnostic process, the role of neuropsychological assessment in the diagnostic process, effects of receiving diagnoses in the absence of a current means of preventing or stopping the progress of Alzheimer’s disease, and treatment recommendations for persons who receive any of these diagnoses.
Now is the time to be engaged in this process, and to let the voices of psychologists who specialize in adult development and aging be heard.
Sincerely,
Cameron J. Camp, Ph.D.
President – Div. 20
